The primary goal in Chronic Myeloid Leukemia (CML) has evolved from survival to tolerability and treatment-free remission. These goals are not uniform; younger patients prioritize stopping treatment to start families, while long-term patients increasingly value better tolerability over marginal efficacy gains.
While tyrosine kinase inhibitors (TKIs) reduced overall CML transplants, a dangerous trend has emerged. Clinicians are waiting too long to transplant high-risk patients, often until after they reach an advanced disease state, which significantly worsens outcomes compared to an early transplant in the chronic phase.
To manage Dasatinib's common side effect of pleural effusions, a randomized study showed that skipping doses on weekends is superior to dose reduction. This strategy leverages the drug's short half-life, maintaining peak levels for efficacy while providing a break from off-target effects that cause toxicity.
While the new CML drug Asciminib demonstrates better efficacy, its most significant advantage is superior tolerability. Clinical trial data shows it causes significantly fewer treatment discontinuations due to adverse events compared to both Imatinib and second-generation TKIs, improving patient adherence and quality of life.
The ASXL1 mutation, found in 11-15% of newly diagnosed CML patients, negates the efficacy benefit of the highly specific BCR-ABL inhibitor Asciminib. This suggests that for this patient subset, Asciminib monotherapy is insufficient, and combination treatments are likely necessary to overcome this form of molecular resistance.
Despite extensive investigation, adding interferon to tyrosine kinase inhibitors (TKIs) does not significantly improve rates of deep molecular response or treatment-free remission in CML. Based on consistent data, its use is no longer recommended except as a bridging therapy for pregnant patients.